KIORA PHARMACEUTICALS INC — Director's Dealing 2021

Jan 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2021-01-06

Reporting Person: ARMISTICE CAPITAL, LLC (Director, 10% Owner)
Reporting Person: Armistice Capital Master Fund Ltd. (Director, 10% Owner)
Reporting Person: Boyd Steven (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-06	Common Stock	P	1531101	$5.225	Acquired	3346601	Direct
2021-01-06	Common Stock	P	0	—	Acquired	3346601	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-06	Warrants	$5.225	P	1531101	Acquired	2025-01-06	Common Stock (1531101)	Direct
2021-01-06	Warrants	$5.225	P	0	Acquired	2025-01-06	Common Stock (0)	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants	$3.125	2024-10-02	Common Stock (600000)	600000	Direct
Warrants	$3.125	2024-10-02	Common Stock (0)	600000	Indirect
Warrants	$0.32	2023-04-17	Common Stock (41666)	41666	Direct
Warrants	$0.32	2023-04-17	Common Stock (0)	41666	Indirect
Warrants	$0.32	2023-04-17	Common Stock (364583)	364583	Direct
Warrants	$0.32	2023-04-17	Common Stock (0)	364583	Indirect
Warrants	$1.50	2022-06-14	Common Stock (133333)	133333	Direct
Warrants	$1.50	2022-06-14	Common Stock (0)	133333	Indirect
Warrants	$0.32	2023-04-17	Common Stock (1062500)	1062500	Direct
Warrants	$0.32	2023-04-17	Common Stock (0)	1062500	Indirect
Series C Convertible Preferred Stock	$0.32		Common Stock (852500)	852500	Direct
Series C Convertible Preferred Stock	$0.32		Common Stock (0)	852500	Indirect

Footnotes

F1: The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.

F2: (Continued from Footnote 1) Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: On January 5, 2021, the Issuer and the Master Fund entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Master Fund acquired from the Issuer in a private placement on the January 6, 2021 closing date: (i) 1,531,101 shares of the Issuer's common stock, $0.01 par value (collectively, the "Shares"); and (ii) warrants to purchase up to 1,531,101 Shares with an exercise price of $5.225 per Share (collectively, the "Warrants"). The aggregate subscription amount paid by the Master Fund for the Shares and Warrants acquired by it pursuant to the Securities Purchase Agreement was $8,000,002.73.

F4: These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 9.99% beneficial owner of the Shares following such exercise.

F5: These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the Shares following such exercise.

F6: The Series C Convertible Preferred Stock has no expiration date and is convertible at any time at the option of the Master Fund.